MDT

99.81

+2.3%↑

137.69

+0.9%↑

VEEV

218.79

+0.25%↑

HQY

84.65

+0.12%↑

NEOG

9.61

+2.67%↑

MDT

99.81

+2.3%↑

137.69

+0.9%↑

VEEV

218.79

+0.25%↑

HQY

84.65

+0.12%↑

NEOG

9.61

+2.67%↑

MDT

99.81

+2.3%↑

137.69

+0.9%↑

VEEV

218.79

+0.25%↑

HQY

84.65

+0.12%↑

NEOG

9.61

+2.67%↑

MDT

99.81

+2.3%↑

137.69

+0.9%↑

VEEV

218.79

+0.25%↑

HQY

84.65

+0.12%↑

NEOG

9.61

+2.67%↑

MDT

99.81

+2.3%↑

137.69

+0.9%↑

VEEV

218.79

+0.25%↑

HQY

84.65

+0.12%↑

NEOG

9.61

+2.67%↑

Kodu・Aktsiate loetelu・Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals Inc

Avatud

SektorTervishoid

1.47 11.36

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.63

Põhinäitajad
By Trading Economics
Sissetulek	-16M -13M
Müük	-15M 14M
Kasumimarginaal	-90.037
Töötajad	103
EBITDA	-16M -10M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+194.16% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	5. märts 2026

Turustatistika
By TradingEconomics
Turukapital	3.6M 498M
Eelmine avamishind	-9.89
Eelmine sulgemishind	1.47

Uudiste sentiment

By Acuity

36%

64%

94 / 361 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Bearish Evidence

0.6863 / 0.72 Toetus ja vastupanu

Lexicon Pharmaceuticals Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

20. jaan 2026, 23:43 UTC

Market Talk

Gold Consolidates; May Face Technical Correction -- Market Talk

20. jaan 2026, 23:42 UTC

Market Talk

Nikkei May Fall Amid Concerns Over U.S.-Europe Trade Relations -- Market Talk

20. jaan 2026, 23:41 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- 2nd Update

20. jaan 2026, 23:29 UTC

Market Talk

RBA Rate Hike in February Would Be a Painful One -- Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

Global Equities Roundup: Market Talk

20. jaan 2026, 23:26 UTC

Market Talk

James Hardie Appeals More as Reece's U.S. Strategy Comes Under Scrutiny -- Market Talk

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol-EG Deal Is First Assessment Subject to Phase 2 Review Under New Merger Control Regime

20. jaan 2026, 22:45 UTC

Omandamised, ülevõtmised, äriostud

ACCC Seeks Submissions in Response to Phase 2 Notice by February 4

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC: Ampol's Offer to Sell 19 Retail Fuel Sites Doesn't Adequately Address Issues

20. jaan 2026, 22:44 UTC

Omandamised, ülevõtmised, äriostud

ACCC Identifies 115 EG Sites Where Deal Could Substantially Lessen Competition

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

ACCC Says Deal Could Substantially Lessen Competition in Retail Supply of Petrol, Diesel in Several Markets in Australia

20. jaan 2026, 22:43 UTC

Omandamised, ülevõtmised, äriostud

Ampol's Acquisition of EG Australia to Undergo In-Depth Review by Competition Regulator

20. jaan 2026, 22:27 UTC

Omandamised, ülevõtmised, äriostud

Netflix Plans to Roll Out New Mobile User Interface Later This Year, Co-CEO Says

20. jaan 2026, 22:25 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO Sees Uptick in Engagement for TV-Based Games

20. jaan 2026, 22:21 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Keep 45-Day Theater Release Window for Warner Bros. Films, Co-CEO Says

20. jaan 2026, 22:20 UTC

Omandamised, ülevõtmised, äriostud

Netflix Excited to Strengthen Warner Bros.'s Theatrical-Distribution Business, Co-CEO Says

20. jaan 2026, 22:19 UTC

Omandamised, ülevõtmised, äriostud

Netflix Pleased With Early Results for Podcasts, Co-CEO Says

20. jaan 2026, 22:18 UTC

Tulu

Netflix Stock Is Falling. This Is Overshadowing the Streamer's Earnings Beat. -- Barrons.com

20. jaan 2026, 22:17 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Live Events Are Boosting Retention, Co-CEO Says

20. jaan 2026, 22:16 UTC

Omandamised, ülevõtmised, äriostud

Netflix Remains 'Very Excited' About Live-Events Offering, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix's Proposed Deal for Warner Bros. Would Protect, Create Jobs, Co-CEO Says

20. jaan 2026, 22:15 UTC

Omandamised, ülevõtmised, äriostud

Netflix Competes for Attention Across Streaming, Broadcast, Cable, Gaming, Social Media, Video Platforms, Co-CEO Says

20. jaan 2026, 22:13 UTC

Omandamised, ülevõtmised, äriostud

Netflix Co-CEO: TV Landscape Has Never Been More Competitive

20. jaan 2026, 22:11 UTC

Omandamised, ülevõtmised, äriostud

Netflix Confident Warner Bros. Deal Would Pass Regulatory Review, Co-CEO Says

20. jaan 2026, 22:10 UTC

Omandamised, ülevõtmised, äriostud

Netflix Would Leverage Global Footprint, Streaming Expertise to Improve Warner Bros.'s HBO Max Service, Co-CEO Says

20. jaan 2026, 22:08 UTC

Omandamised, ülevõtmised, äriostud

Netflix Won't Raise Prices During Regulatory-Review Process for Pending Warner Bros. Deal, Co-CEO Says

20. jaan 2026, 22:07 UTC

Omandamised, ülevõtmised, äriostud

Netflix Sees Warner Bros. as Another Mechanism to Improve Offerings, Co-CEO Says

20. jaan 2026, 22:06 UTC

Tulu

Netflix Revenue and Profit Rise as Subscriptions Top 325 Million -- Update

20. jaan 2026, 22:00 UTC

Market Talk

Omandamised, ülevõtmised, äriostud

ESG Roundup: Market Talk

20. jaan 2026, 21:50 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Lexicon Pharmaceuticals Inc Prognoos

Hinnasiht

By TipRanks

194.16% tõus

12 kuu keskmine prognoos

Keskmine 4.03 USD 194.16%

Kõrge 6 USD

Madal 2.1 USD

Põhineb 3 Wall Streeti analüütiku instrumendi Lexicon Pharmaceuticals Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

3 ratings

Osta

Hoia

Müü

Põhineb 3 analüütiku instrumendi Lexicon Pharmaceuticals Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.6863 / 0.72Toetus ja vastupanu

Recent bearish events outweigh bullish events.

All events are bullish.

There is one bearish event.

Sentiment

By Acuity

94 / 361 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.